The Current Role of Osteoclast Inhibitors in Patients with Prostate Cancer
Open Access
- 26 December 2018
- journal article
- review article
- Published by Wiley in Advances in Urology
- Vol. 2018, 1-9
Abstract
Purpose. Prostate cancer (PCa) is one of the most frequently diagnosed malignancies worldwide. Hormonal deprivation therapy is a well-established treatment for locally advanced or metastatic diseases but exposes patients to the risk of osteoporosis and fragility fractures. Furthermore, the tropism of the PCa cells to osseous metastases increases the incidence of skeletal-related events (SREs). Methods. A nonsystematic review of the international literature was performed in respect to the use of osteoclast inhibitors zoledronic acid (ZA) and denosumab (DEN) in PCa patients. Results. DEN and ZA have proved their efficacy in preventing osteoporosis and bone mass loss in patients treated with hormonal therapy with no proven superiority of one agent over the other. However, the effectiveness in reducing fragility fractures has been proved only for DEN so far. In metastatic-free castrate-sensitive high-risk PCa patients, ZA has not shown any efficacy in preventing osseous metastasis, and evidence is lacking in favor or against the use of DEN. The use of osteoclasts inhibitors had no evident positive effect in overall and disease-specific survival in this group of patients. In advanced castrate-refractory malignancy, DEN has shown clinical superiority over ZA in preventing new SRE but not in overall survival. Conclusion. Superiority of DEN over ZA has been proved only in advanced castrate refractory disease in terms of preventing new SRE. In the rest of the cases, the selection of either agent should be based on the clinical condition of each patient and the cost of the treatment.Keywords
This publication has 36 references indexed in Scilit:
- Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatmentsInflammopharmacology, 2013
- Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastasesMedical Oncology, 2013
- Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trialThe Lancet, 2012
- 70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate CancerJournal of Urology, 2009
- Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trialsThe Lancet Oncology, 2009
- Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate CancerNew England Journal of Medicine, 2009
- Zoledronic Acid Initiated During the First Year of Androgen Deprivation Therapy Increases Bone Mineral Density in Patients With Prostate CancerJournal of Urology, 2006
- Randomized, Double-Blind, Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone and Placebo in Patients With Hormone-Refractory Prostate Cancer and PainJournal of Clinical Oncology, 2003